Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorShanghai East Hospital
About this trial
In this study, the investigators intend to utilize 68Ga-Pentixafor Positron Emission Tomography（PET） imaging for patients diagnosed with non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). The investigators will compare the imaging results with those obtained from 18F-FDG imaging, and a correlation analysis will be performed to assess progression-free survival among patients. This analysis aims to evaluate the diagnostic efficacy and the potential for early prediction of treatment efficacy associated with 68Ga-Pentixafor in these specific conditions.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age of 18 years or older
ECOG < 2
Newly diagnosed patients with NHL and MM who have been confirmed or are highly suspected based on pathological examination
Completion of 18F-FDG PET/CT or PET/MR imaging within the past week in our department
Disqualifiers
Pregnant and breastfeeding women;
Individuals with severe hepatic and renal failure;
Patients with concurrent malignancies;
Individuals unable to remain supine for a duration of 30 minutes to complete the examination;
Trial population
All patients who meet the inclusion and exclusion criteria and are willing to follow the research process.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
30 Participants
are grouped into 1 trial groupGroup A: Research group
Trial outcomes
Primary outcomes
1
Ann Arbor staging
All patients were classified into stages I-IV based on Ann Arbor staging according to visual methods.
Time frame
After the patient signs the informed consent form and completes the scan, an average of 2 days.2
Metabolic parameters
Calculate maximum standardized uptake value (SUVmax (lesion)) of all affected lymphoma and extranodal organs. Set a region of interest with a diameter of approximately 10mm in the descending segment of the thoracic aorta, calculate the standardized uptake value (SUVmean) of the mediastinal blood pool, calculate SUVmax (lesion)/SUVmean (blood pool).
Time frame
After the patient signs the informed consent form and completes the scan, an average of 2 days.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: